الفهرس 
INTRODUCTION AND RATIONALEOnly 14 pages are availabe for public view
 |  | from | 134 |  |  |
| | | from | 134 | | |
Abstract
Toxoplasmosis is a parasitic disease with global distribution. It is responsible for significant morbidity and mortality, especially in congenitally infected and immunocompromised individuals. Currently, there is no vaccine available to prevent human infection. Although the current medicine is effective against tachyzoites in the acute stage of the disease, they do not completely eradicate encysted latent bradyzoites or clear all cysts. Furthermore, these therapies can be associated with serious side effects. Accordingly, new safe and effective drugs with novel mechanisms of action are urgently needed.
In the search for new strategies that overcome the drawbacks of previous treatment regimens, nanoparticles find their way as trial agents against toxoplasmosis. It is well established that CUR has a long history in medicine because of its considerable pharmacological properties and anti-inflammatory activities. Over the past decade, anti-protozoal potential of CUR was demonstrated in vitro and in vivo research. The poor bioavailability and the chemical instability of curcuminoids are of major concern. To overcome these shortcomings, the present study reports a novel approach for the delivery of CUR when formulated as nanoemulsion. The present study was conducted to evaluate the prophylactic and therapeutic effect(s) of CUR nanoemulsion in T. gondii experimentally infected mice regarding survival rate, reduction in parasite count and morphological changes in the parasite.
Experimental mice were divided into three groups, group I (5 mice) a control negative group, group II (40 mice) to assess the prophylactic and therapeutic effects of CUR nanoemulsion on RH infected mice and group III (30 mice) to assess the therapeutic effect of CUR nanoemulsion on ME49 infected mice.
This study showed the following results:
Acute toxoplasmosis (